Immunohistological Analyses of Neutral Glycosphingolipids and Gangliosides in Normal Mouse Skeletal Muscle and in Mice with Neuromuscular Diseases

Overview

Journal Glycoconj J

Publisher Springer

Specialties Biochemistry
Endocrinology

Date 1995 Oct 1

PMID 8595265

Citations 5

Authors

M Cacic

K Sostaric

J Muthing

Affiliations

Soon will be listed here.

Abstract

The expression of neutral glycosphingolipids (GSLs) and gangliosides was investigated in cryosections of normal mouse skeletal muscle and in muscle of mice with neuromuscular diseases using indirect immunofluorescence microscopy. Transversal and longitudinal sections were immunostained with specific polyclonal antibodies against lactosylceramide, lacto-N-neotetraosylceramide, globoside, GM3(Neu5Ac), GM3(Neu5Gc) and Gm1(Neu5Ac) as well as monoclonal anti-Forssman GSL antibody. In normal CBA/J mouse muscle (control) the main immunohistochemically detected ganglioside was GM3(Neu5Ac) followed by moderately expressed GM3(Neu5Gc) and GM1. The neutral GSLs lactosylceramide and globoside were stained with almost identical, high fluorescence intensity. Low amounts of lacto-N-neotetraosylceramide and trace quantities of Forssman GSL were immunostained. All GSLs were detected in the sarcolemma, but also in considerable amounts at the intracellular level. Mice with neuromuscular diseases were the A2G-adr mouse mutant (a model for human recessive myotonia of Becker type), the BL6-wr mutant (a model for motor neuron disease) and the BL10-mdx mouse mutant (a model for human Duchenne muscular dystrophy). No changes in GSL expression were found in the A2G-adr mouse, while muscle of the BL6-wr mouse showed increased intensity of immunofluorescence in stainings with anti-lactosylceramide and anti-GM3(Neu5Ac) antibodies. Muscle of BL10-mdx mice showed the most prominent changes in GSL expression with reduced fluorescence intensity for all antibodies. Major differences were not observed in the intensities of GSLs, but there were significant differences in the patterns of distribution on plasma membrane and at the subcellular level. The exact nature and pathogenesis of these changes should be elucidated since such investigations could furnish advances in understanding the functional role of neutral GSLs and gangliosides in normal as well as in diseased muscle.

Citing Articles

Sphingolipids in Obesity and Correlated Co-Morbidities: The Contribution of Gender, Age and Environment.

Torretta E, Barbacini P, Al-Daghri N, Gelfi C Int J Mol Sci. 2019; 20(23).

PMID: 31771303 PMC: 6929069. DOI: 10.3390/ijms20235901.

Lipid glycosylation: a primer for histochemists and cell biologists.

Kopitz J Histochem Cell Biol. 2016; 147(2):175-198.

PMID: 27999995 DOI: 10.1007/s00418-016-1518-4.

Implications for the mammalian sialidases in the physiopathology of skeletal muscle.

Fanzani A, Zanola A, Faggi F, Papini N, Venerando B, Tettamanti G Skelet Muscle. 2012; 2(1):23.

PMID: 23114189 PMC: 3534598. DOI: 10.1186/2044-5040-2-23.

Ganglioside GM3 levels are altered in a mouse model of HIBM: GM3 as a cellular marker of the disease.

Paccalet T, Coulombe Z, Tremblay J PLoS One. 2010; 5(4):e10055.

PMID: 20383336 PMC: 2850932. DOI: 10.1371/journal.pone.0010055.

Glycosphingolipid expression in human skeletal and heart muscle assessed by immunostaining thin-layer chromatography.

Muthing J, Cacic M Glycoconj J. 1997; 14(1):19-28.

PMID: 9076510 DOI: 10.1023/a:1018552729572.

References

Bassi S, Albizzati M, Calloni E, Frattola L . Electromyographic study of diabetic and alcoholic polyneuropathic patients treated with gangliosides. Muscle Nerve. 1982; 5(5):351-6. DOI: 10.1002/mus.880050503. View

Gahmberg C, HAKOMORI S . External labeling of cell surface galactose and galactosamine in glycolipid and glycoprotein of human erythrocytes. J Biol Chem. 1973; 248(12):4311-7. View

Hallett M, Flood T, Slater N, Dambrosia J . Trial of ganglioside therapy for diabetic neuropathy. Muscle Nerve. 1987; 10(9):822-5. DOI: 10.1002/mus.880100907. View

Andrews J . The fine structure of the cervical spinal cord, ventral root and brachial nerves in the wobbler (wr) mouse. J Neuropathol Exp Neurol. 1975; 34(1):12-27. DOI: 10.1097/00005072-197501000-00002. View

Norido F, Canella R, Gorio A . Ganglioside treatment of neuropathy in diabetic mice. Muscle Nerve. 1982; 5(2):107-10. DOI: 10.1002/mus.880050205. View

Hoffman E, Brown Jr R, Kunkel L . Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell. 1987; 51(6):919-28. DOI: 10.1016/0092-8674(87)90579-4. View

Muthing J, Neumann U . Selective detection of terminally alpha 2-3 and alpha 2-6 sialylated neolacto-series gangliosides by immunostaining on thin layer chromatograms. Biomed Chromatogr. 1993; 7(3):158-61. DOI: 10.1002/bmc.1130070312. View

Koch M, Steinmeyer K, Lorenz C, Ricker K, Wolf F, Otto M . The skeletal muscle chloride channel in dominant and recessive human myotonia. Science. 1992; 257(5071):797-800. DOI: 10.1126/science.1379744. View

Cacic M, Muthing J, Kracun I, Neumann U . Expression of neutral glycosphingolipids and gangliosides in human skeletal and heart muscle determined by indirect immunofluorescence staining. Glycoconj J. 1994; 11(5):477-85. DOI: 10.1007/BF00731284. View

10.

Iannello R, Jeffrey P . Denervation-induced changes in lectin binding to sarcolemmal glycoproteins: exposure of cryptic recognition sites. Glycobiology. 1992; 2(3):211-6. DOI: 10.1093/glycob/2.3.211. View

11.

Mehrke G, Brinkmeier H, Jockusch H . The myotonic mouse mutant ADR: electrophysiology of the muscle fiber. Muscle Nerve. 1988; 11(5):440-6. DOI: 10.1002/mus.880110505. View

12.

Gillard B, Thurmon L, Marcus D . Variable subcellular localization of glycosphingolipids. Glycobiology. 1993; 3(1):57-67. DOI: 10.1093/glycob/3.1.57. View

13.

Steinmeyer K, Lorenz C, Pusch M, Koch M, Jentsch T . Multimeric structure of ClC-1 chloride channel revealed by mutations in dominant myotonia congenita (Thomsen). EMBO J. 1994; 13(4):737-43. PMC: 394869. DOI: 10.1002/j.1460-2075.1994.tb06315.x. View

14.

Mengs U, Goldschmidt R, Tullner H . Effect of ganglioside treatment on number of nerve fibres after nerve crush in rats. Arch Int Pharmacodyn Ther. 1986; 283(2):229-36. View

15.

Muthing J, Steuer H, Peter-Katalinic J, Marx U, Bethke U, Neumann U . Expression of gangliosides GM3 (NeuAc) and GM3 (NeuGc) in myelomas and hybridomas of mouse, rat, and human origin. J Biochem. 1994; 116(1):64-73. DOI: 10.1093/oxfordjournals.jbchem.a124504. View

16.

Marcus D, Janis R . Localization of glycosphingolipids in human tissues by immunofluorescence. J Immunol. 1970; 104(6):1530-9. View

17.

Igarashi Y, Nojiri H, Hanai N, Hakomori S . Gangliosides that modulate membrane protein function. Methods Enzymol. 1989; 179:521-41. DOI: 10.1016/0076-6879(89)79152-7. View

18.

Caccia M, Meola G, Cerri C, Frattola L, Scarlato G, Aporti F . Treatment of denervated muscle by gangliosides. Muscle Nerve. 1979; 2(5):382-9. DOI: 10.1002/mus.880020510. View

19.

Bulfield G, Siller W, Wight P, Moore K . X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc Natl Acad Sci U S A. 1984; 81(4):1189-92. PMC: 344791. DOI: 10.1073/pnas.81.4.1189. View

20.

Steinmeyer K, Klocke R, Ortland C, Gronemeier M, Jockusch H, Grunder S . Inactivation of muscle chloride channel by transposon insertion in myotonic mice. Nature. 1991; 354(6351):304-8. DOI: 10.1038/354304a0. View